237 results on '"Goce, Spasovski"'
Search Results
202. Atypical Vascular Access for Dialysis Patients via Persistent Left Superior Vena Cava
- Author
-
Nihad Kukavica, Halima Resić, and Goce Spasovski
- Subjects
medicine.medical_specialty ,Nephrology ,business.industry ,Vascular access ,medicine ,Hematology ,Persistent left superior vena cava ,Dialysis patients ,business ,medicine.disease ,Surgery - Published
- 2014
203. Late diagnosis of primary hyperoxaluria after failed kidney transplantation
- Author
-
Nenad Blau, Bodo B. Beck, Velibor Tasic, Bernd Hoppe, Goce Spasovski, University of Zurich, and Spasovski, G
- Subjects
Nephrology ,2748 Urology ,medicine.medical_specialty ,Calcium Oxalate Crystal Deposition ,Pathology ,Delayed Diagnosis ,Urology ,610 Medicine & health ,urologic and male genital diseases ,Kidney ,Gastroenterology ,End stage renal disease ,Primary hyperoxaluria ,Internal medicine ,medicine ,Humans ,Treatment Failure ,Diagnostic Errors ,Kidney transplantation ,Oxalates ,2727 Nephrology ,business.industry ,Kidney metabolism ,Middle Aged ,medicine.disease ,Kidney Transplantation ,female genital diseases and pregnancy complications ,Nephrocalcinosis ,medicine.anatomical_structure ,10036 Medical Clinic ,Hyperoxaluria, Primary ,Kidney Failure, Chronic ,Female ,Primary Graft Dysfunction ,business - Abstract
Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive inborn error of the glyoxylate metabolism that is based on absence, deficiency or mislocalization of the liver-specific peroxisomal enzyme alanine:glyoxylate aminotransferase. Hyperoxaluria leads to recurrent formation of calculi and/or nephrocalcinosis and often early end-stage renal disease (ESRD) accompanied by systemic calcium oxalate crystal deposition. In this report, we describe an adult female patient with only one stone passage before development of ESRD. With unknown diagnosis of PH, the patient received an isolated kidney graft and developed an early onset of graft failure. Although initially presumed as an acute rejection, the biopsy revealed calcium oxalate crystals, which then raised a suspicion of primary hyperoxaluria. The diagnosis was later confirmed by hyperoxaluria, elevated plasma oxalate levels and mutation of the AGXT gene, showing the patient to be compound heterozygous for the c.33_34InsC and c.508G > A mutations. Plasma oxalate levels did not decrease after high-dose pyridoxine treatment. Based on this case report, we would recommend in all patients even with a minor history of nephrolithiasis but progression to chronic renal failure to exclude primary hyperoxaluria before isolated kidney transplantation is considered.
- Published
- 2009
204. Successful treatment of severe secondary hyperparathyroidsm (Brown tumor) by kidney transplantation and pulses of oral calcitriol
- Author
-
Goce Spasovski, Daniel Gjurchinov, and Jelka Masin-Spasovska
- Subjects
Transplantation ,medicine.medical_specialty ,Kidney ,Hyperparathyroidism ,Bone disease ,business.industry ,Osteitis Fibrosa Cystica ,Ribs ,medicine.disease ,Kidney Transplantation ,Surgery ,Brown tumor ,Young Adult ,medicine.anatomical_structure ,Medicine ,Humans ,Kidney Failure, Chronic ,Secondary hyperparathyroidism ,Parathyroid gland ,Female ,Hyperparathyroidism, Secondary ,business ,Kidney transplantation - Abstract
Brown tumor is an extreme form of severe hyperparathyroid bone disease in end-stage renal disease patients. The evolution of the tumor after renal transplantation and under conservative treatment is still unclear. Herein, we report a 22-yr-old girl with parathyroid glandular hyperplasia because of an inadequate compliance and control of the mineral metabolism and subsequently developed Brown tumor of the ribs. A gradual improvement in bone and parathyroid gland status was observed within three yr following successful kidney transplantation and treatment with pulses of oral calcitriol. To the best of our knowledge, this is the first case of such severe secondary hyperparathyroidism with successful conservative treatment in the setting of kidney transplantation with no evidence of vascular calcifications and graft failure.
- Published
- 2009
205. The role of EUTox in uremic toxin research
- Author
-
Achim Jörres, Joachim Beige, Peter Brouckaert, Alessandra F. Perna, Ulrich Baurmeister, Goce Spasovski, Joachim Jankowski, Bernd Stegmayr, Griet Glorieux, Tilman B. Drüeke, Andrzej Wiecek, A. Argiles, Gerald Cohen, Philippe Brunet, Peter Paul De Deyn, Danilo Fliser, Paul J. Thornalley, Ziad A. Massy, Christoph Wanner, Raymond Vanholder, Stefan Herget-Rosenthal, Harald Mischak, Omar Abou-Deif, Juan Mariano Rodriguez-Portillo, Peter Stenvinkel, Walter H. Hörl, Vanholder, R, ABOU DEIF, O, Argiles, A, Baurmeister, U, Beige, J, Brouckaert, P, Brunet, P, Cohen, G, DE DEYN, Pp, Drüeke, Tb, Fliser, D, Glorieux, G, HERGET ROSENTHAL, S, Hörl, Wh, Jankowski, J, Jörres, A, Massy, Za, Mischak, H, Perna, Alessandra, RODRIGUEZ PORTILLO, Jm, Spasovski, G, Stegmayr, Bg, Stenvinkel, P, Thornalley, Pj, Wanner, C, and Wiecek, A.
- Subjects
medicine.medical_specialty ,Biomedical Research ,Research groups ,Databases, Factual ,Information Dissemination ,business.industry ,European research ,Advisory Committees ,MEDLINE ,Original research ,Bench to bedside ,Europe ,Nephrology ,Family medicine ,Immunology ,Uremic toxins ,Humans ,Medicine ,Human medicine ,business ,Relevant information ,Toxins, Biological ,Uremia - Abstract
In this publication, we review the activities of the European Uremic Toxin Work Group (EUTox) in the field of uremic toxin research. Founded in 1999 under the umbrella of the European Society of Artificial Organs (ESAO), and active since 2000, this group focuses essentially on questions related to solute retention and removal during chronic kidney disease, and on the deleterious impact of those solutes on biological/biochemical systems. As of January 1, 2009, the group had met 28 times; it organized the third meeting, "Uremic Toxins in Cardiovascular Disease," which took place in October 2008 in Amiens, France. The current group is composed of 25 members belonging to 23 European research institutions. As of November 1, 2008, in total 69 papers had been published to which at least two different research groups belonging to EUTox have contributed in a collaborative effort. Of these, 40 papers were on original research and eight were specific EUTox reviews or position statements. A website (http://www.eutox.info) summarizes all relevant information concerning the work group. EUTox also developed an interactive uremic toxin database, where concentrations of known toxins are displayed, to be used by researchers in the field. In the future, EUTox intends to continue its focus on bench to bedside research with specific consideration of proteomics, metabonomics, secretomics, and genomics. © 2009 Wiley Periodicals, Inc.
- Published
- 2009
206. Balkan endemic nephropathy: a still unsolved puzzle
- Author
-
Adalbert, Schiller, Paul, Gusbeth-Tatomir, Nikola, Pavlovic, Dusan, Ferluga, Goce, Spasovski, and Adrian, Covic
- Subjects
Balkan Nephropathy ,Humans ,Kidney - Abstract
Balkan endemic nephropathy (BEN) is a chronic tubulointerstitial renal disease, occurring in certain regions in 5 countries of the Balkan peninsula. Its etiology is largely unknown, though several hypotheses have been formulated and are discussed in this review. In several cases, etiological hypotheses (e.g., viral, ochratoxin or trace element involvement) are verified only in local endemic areas and can not be confirmed when tested elsewhere. Only certain families in the endemic areas are affected. An exposure of at least 20 years to the unknown factors in the endemic areas seems to be mandatory for the development of the disease, but a genetic predisposition to this disease also seems to be mandatory. Prominent clinical features are severely shrunken kidneys, a more severe anemia relative to the level of renal function, and a slow progression to end-stage renal failure. An international approach to solving the etiological and pathogenetic enigma of BEN is needed in the coming years. It is also time to reevaluate other chronic, slowly progressive tubulointerstitial nephropathies diagnosed elsewhere in the world and to search for possible etiological similarities with BEN.
- Published
- 2008
207. Low turn-over bone disease in patients with chronic renal disease
- Author
-
Goce, Spasovski
- Subjects
Chronic Kidney Disease-Mineral and Bone Disorder ,Humans ,Hyperparathyroidism, Secondary - Abstract
During the last decades, the prevalence of various types of renal osteodystrophy has been changed from a high to low bone turnover. Besides the established conventional risk factors, the existence of a dynamic bone disease as most prevalent form of renal osteodystrophy nowadays and its reduced ability to handle an exogenous calcium load has implied a higher risk for vascular calcification, morbidity and mortality in the dialysis population. Calcium-based phosphate binders are inexpensive and efficient but their extended and/or inappropriate use, particularly when used in combination with vitamin D analogues, may contribute to the development of adynamic bone disease and promotion of soft-tissue and vascular calcification. It seems reasonable to reduce the number of calcium carbonate/acetate tablets to only 1 g/day in order to increase serum phosphate and decrease serum calcium, which both in turn might positively stimulate the parathyroid hormone secretion. Low calcium dialysate (1.25 mmol/l) was reported to have an impact on the evolution towards markers reflecting higher bone turnover, most probably by prevention of a positive calcium balance, enabling sustained stimulation of parathyroid hormone secretion. Hence, the two reasonable strategies should be employed together in order to prevent consequences related to adynamic bone disease and to contribute to a better long-term quality of life and survival of dialysis patients.
- Published
- 2008
208. European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP)
- Author
-
Francesco Locatelli, Jorge B. Cannata-Andía, Kai-Uwe Eckardt, Daniel Abramowicz, Elizabeth Lindley, Goce Spasovski, Adrian Covic, Olof Heimbürger, Denis Fouque, James Tattersall, Alison McLeod, Raymond Vanholder, Carmine Zoccali, C Wanner, Pierre Cochat, and Wim van Biesen
- Subjects
Transplantation ,medicine.medical_specialty ,Evidence-Based Medicine ,business.industry ,Best practice ,Judgement ,MEDLINE ,Guidelines as Topic ,Evidence-based medicine ,Evidence level ,Kidney Transplantation ,Europe ,Nephrology ,Renal Dialysis ,Family medicine ,Medicine ,Humans ,Kidney Diseases ,Workgroup ,business ,Intensive care medicine ,Rename ,Societies, Medical - Abstract
Although medical guidelines generally are graded according to their evidence level, low evidence 'judgement' are generally perceived as much as absolute truth by the medical community as high evidence 'guidelines' are. Being aware of this bias, a workgroup appointed by the European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA), the members of which are the authors of the current publication, decided that European nephrology guidelines issued by the Association should be published only as 'guidelines' in the case of high-level evidence; otherwise they should be named 'recommendations' or 'position statements' and be published in a different format. Acknowledging that in nephrology, high levels of evidence are often lacking, it was also decided to rename the responsible body from European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). The present publication reviews the arguments based on which this decision was taken.
- Published
- 2008
209. Vascular calcification and atherosclerosis in hemodialysis patients: what can we learn from the routine clinical practice?
- Author
-
Zoran Trajkovski, Vili Amitov, Aleksandar Sikole, Goge Damjanovski, Sonja Dzikova, Saso Gelev, and Goce Spasovski
- Subjects
Vitamin ,Nephrology ,Adult ,Male ,medicine.medical_specialty ,Urology ,Radiography ,medicine.medical_treatment ,Population ,Gastroenterology ,Bone remodeling ,chemistry.chemical_compound ,Renal Dialysis ,Risk Factors ,Internal medicine ,medicine ,Humans ,Vascular Diseases ,education ,Aged ,Ultrasonography ,Aged, 80 and over ,education.field_of_study ,Analysis of Variance ,Chi-Square Distribution ,business.industry ,Calcinosis ,Middle Aged ,medicine.disease ,Atherosclerosis ,Arterial calcification ,Cross-Sectional Studies ,chemistry ,Cardiology ,Kidney Failure, Chronic ,Female ,Hemodialysis ,business ,Kidney disease - Abstract
Hemodialysis (HD) patients are at increased risk for arterial intimal (AIC) and medial calcification (AMC). In a cross-sectional study on 153 HD patients we evaluated the presence of AIC and AMC using plain radiography of the pelvis and the presence of atherosclerotic lesions using high-resolution B-mode ultrasonography of the common carotid arteries (CCA). The radiography of the pelvis confirmed the frequent presence of AIC (35.3%) and AMC (35.9%) in our HD patients. Arterial calcification was absent (non calcified—NC) in a minority of patients (28.8%). Patients with AIC had significantly higher prevalence of atherosclerotic plaques on CCA (78.6%) compared with both other groups and a higher number of documented atherosclerotic complications, such as cardiovascular (85.2%), cerebrovascular (33.3%) and peripheral arterial disease (38.9%) in comparison with the NC patients. According to the 1-year calculated data from patient records, there were no significant differences in the specific HD risks, such as the dose of prescribed calcium carbonate and vitamin D3, serum levels of calcium, phosphate, calcium-phosphate product and intact parathyroid hormone. All four bone metabolism markers within the range proposed by K/DOQI guidelines were achieved in 9.3%, 14.5% and 20.4% in the AIC, AMC and NC group, respectively. Patients with AIC and AMC are frequently found in the HD population. Screening for arterial calcifications in chronic kidney disease patients is suggested even in the early pre-dialysis period. The highest proportion of patients within the guidelines proposed range for bone and mineral metabolism markers was observed in the NC group. A longer period of data analysis is required in order to evaluate the possible role of some traditional and HD-specific risk factors for the development of arterial calcifications. The achievement of the K/DOQI guidelines is an important issue in the prevention of those conditions.
- Published
- 2007
210. Bone health and vascular calcification relationships in chronic kidney disease
- Author
-
Goce Spasovski
- Subjects
medicine.medical_specialty ,Hypercalcaemia ,Calcitriol ,Hypophosphatemia ,Urology ,Parathyroid hormone ,chemistry.chemical_element ,Calcium ,Bone remodeling ,Phosphates ,Internal medicine ,Medicine ,Humans ,Hypocalcaemia ,Hyperparathyroidism ,business.industry ,medicine.disease ,Endocrinology ,chemistry ,Nephrology ,Hypercalcemia ,Kidney Failure, Chronic ,Secondary hyperparathyroidism ,Hyperparathyroidism, Secondary ,Bone Diseases ,business ,medicine.drug - Abstract
Abnormal bone in chronic kidney disease (CKD) may adversely affect vascular calcification via disordered calcium and phosphate metabolism. In this context, bone health should be viewed as a prerequisite for the successful prevention/treatment of vascular calcification (VC) along with controlled parathyroid hormone (PTH) secretion, the use of calcium-based phosphate binders and vitamin D therapy. In CKD patients, VC occurs more frequently and progresses more rapidly than in the general population, and is associated with increased cardiovascular disease (CVD) morbidity and mortality. A number of therapies aimed at reducing PTH concentration are associated with an increase of calcaemia and Ca x P product, e.g. calcium-containing phosphate binders or active vitamin D. The introduction of calcium-free phosphate binders has reduced calcium load, attenuating VC and improving trabecular bone content. In addition, a major breakthrough has been achieved through the use of calcimimetics, as first agents which lower PTH without increasing the concentrations of serum calcium and phosphate. Nowadays, it is becoming evident that even early stage CKD is recognised as an independent CVD risk factor. Moreover, the excess of CVD among dialysis patients cannot be explained entirely on the basis of abnormal mineral and bone metabolism. Hence, much controversy has surrounded the cost-effectiveness of treatment with the new phosphate-binding drugs as well as new vitamin D analogs and calcimimetics. Thus, it seems prudent and reasonable that maintaining bone health and mineral homeostasis should rely on some modifications of standard phosphate binding and calcitriol therapy. Hypophosphataemia and hypercalcaemia in adynamic bone disease (ABD) might be treated by reducing the number of calcium carbonate/acetate tablets in order to increase serum phosphate and decrease serum calcium, which, in turn, might positively stimulate PTH secretion. The same rationale is assumed for the use of a low calcium dialysate. On the other hand, secondary hyperparathyroidism with hyperphosphataemia and hypocalcaemia should be treated with a substantial number of calcium carbonate/acetate tablets in combination with calcitriol and low calcium dialysate in order to decrease serum phosphate and maintain the Ca x P product within K/DOQI guidelines (
- Published
- 2007
211. Inconsistency of reported uremic toxin concentrations
- Author
-
Eva Schepers, Bernd Stegmayr, Natalie Meert, Goce Spasovski, Raymond Vanholder, Rita De Smet, Ziad A. Massy, Walter Zidek, Tilman B. Drüeke, Gerald Cohen, Àngel Argilés, Reinhold Deppisch, and Joachim Jankowski
- Subjects
Chromatography ,Chemistry ,Toxin ,Uremic toxicity ,Biomedical Engineering ,Medicine (miscellaneous) ,Bioengineering ,General Medicine ,medicine.disease_cause ,Biomaterials ,Uremic toxins ,medicine ,Humans ,Biomarkers ,Uremia - Abstract
Discrepancies in reported uremic toxin concentrations were evaluated for 78 retention solutes. For this analysis, 378 publications were screened. Up to eight publications per toxin were retained. The highest and the lowest reported concentrations, as well as the median reported concentration were registered. The ratio between the highest and the lowest (H/L) concentrations and, for some solutes, also the ratio between the highest and the median (H/M) concentrations were calculated. The compounds were arbitrarily subdivided into three groups based on their H/L ratio: group A, H/L3 (n = 33); group B, 3H/L8.5 (n = 20); and group C, H/L8.5 (n = 25). Solutes of groups A and B showed a low to intermediate scatter, suggesting a homogeneity of reported data. Group C showed a more substantial scatter. For at least 10 compounds of group C, extremely divergent concentrations were registered (H/M5.5) using scatter plot analysis. For all solutes of groups A and B, the highest reported concentration could be used as a reference. For some solutes of group C and for the compounds showing a divergent scatter analysis, however, more refined directives should be followed.
- Published
- 2007
212. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium
- Author
-
Aleksandar Sikole, Raymond Vanholder, Jelka Masin-Spasovska, Goce Spasovski, Gjulsen Selim, and Saso Gelev
- Subjects
Male ,medicine.medical_specialty ,Histology ,Time Factors ,Physiology ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Parathyroid hormone ,chemistry.chemical_element ,Peptide hormone ,Calcium ,Bone remodeling ,Bone Density ,Internal medicine ,Dialysis Solutions ,medicine ,Humans ,Renal osteodystrophy ,Dialysis ,Kidney ,Dose-Response Relationship, Drug ,business.industry ,Middle Aged ,medicine.disease ,Dose–response relationship ,Endocrinology ,medicine.anatomical_structure ,chemistry ,Female ,Bone Diseases ,business ,Biomarkers - Abstract
The existence of adynamic bone disease (ABD) as most prevalent form of renal osteodystrophy in recent years and its reduced ability to handle an exogenous calcium load has implied a higher risk for vascular and soft-tissue calcifications. The effect of low dialysate calcium (LCD) on parathyroid hormone (PTH) secretion in ABD patients has not yet sufficiently been clarified. This randomized, prospective study aimed to compare the effects of LCD and high calcium dialysate (HCD) on the evolution of bone and mineral parameters related to ABD in dialysis patients.52 out of 60 patients with predialysis intact PTH100 pg/ml completed this study and were equally distributed over LCD (1.25 mmol/l) or HCD (1.75 mmol/l) treatment. The duration of the study was 6 months and the only peroral phosphate binder administered was calcium carbonate. Total and ionised calcium were measured monthly in serum before and after dialysis while serum parameters relevant to bone were measured at the enrollment and at 3-month intervals.There were no differences in predialysis mean phosphate or calcium x phosphorus product (Ca x P). The most common side effects of both treatments were comparable. Hypotension occurred in 16% and 17% and cramps in 6% and 8% of the dialysis sessions, in the HCD and LCD group, respectively. The groups did not differ in the mean tCa before dialysis, but this parameter was significantly higher in the HCD group vs. LCD at the end of dialysis (2.59+/-0.18 vs. 2.44+/-0.19 mmol/l; p0.01). The patients of the HCD group also had a significantly higher mean iCa both before (1.08+/-0.05 vs. 1.04+/-0.06 mmol/l; p=0.02) and at the end of dialysis (1.18+/-0.04 vs. 1.48+/-0.04 mmol/l; p0.01). There were no differences within the LCD group between baseline and end of dialysis treatment values of tCa and iCa. However, the mean tCa and iCa were markedly increased at the end of dialysis in the HDC group [2.40+/-0.21 vs. 2.59+/-0.18 mmol/l (p0.01); 1.08+/-0.05 vs. 1.18+/-0.04 mmol/l (p0.01)]. Mean serum levels of iPTH and total alkaline phosphatase in the LCD group were increased at 3 months and at the end of the study compared with the baseline levels [(38.6+/-22.9 vs. 63.3+/-46.0 vs. 78.6+/-44.7 pg/ml); (59.5+/-18.7 vs. 75.9+/-26.7 vs. 84.0+/-35.4 U/l)], respectively, and bone alkaline phosphatase increased also only after 6 months of treatment (23.4+/-7.3 U/l vs. 35.6+/-22.3). The bone markers in the HCD group did not change. At the end of the study all bone parameters in the LCD group were significantly higher than in the HCD group.There was an evolution towards parameters reflecting higher bone turnover in patients treated with dialysate calcium of 1.25 mmol/l, probably by prevention of a positive calcium balance and enabling sustained stimulation of PTH secretion. Hence, LCD might be considered a valuable therapeutic option for ABD patients.
- Published
- 2007
213. SP919PRIMARY HYPEROXALURIA TYPE 1 - CLINICAL GENETIC AND PROGNOSTIC FEATURES OF MACEDONIAN PATIENTS
- Author
-
Goce Spasovski, Momir Polenakovic, Velibor Tasic, and Zoran Gucev
- Subjects
Transplantation ,medicine.medical_specialty ,Type (biology) ,Nephrology ,business.industry ,Internal medicine ,Clinical genetic ,language ,Medicine ,Macedonian ,business ,language.human_language - Published
- 2015
214. FP308URINARY PROTEOMICS TO DECIPHER MOLECULAR PATHOPHYSIOLOGY OF CKD PROGRESSION
- Author
-
Harald Mischak, Griet Glorieux, Katerina Markoska, Szymon Filip, Raymond Vanholder, J.P. Schanstra, Antonia Vlahou, William Mullen, Joachim Jankowski, Theofilos Papadopoulos, Goce Spasovski, and Jerome Zoidakis
- Subjects
Transplantation ,Nephrology ,business.industry ,Medicine ,DECIPHER ,Bioinformatics ,business ,Proteomics ,Pathophysiology - Published
- 2015
215. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up
- Author
-
Patrick C. D'Haese, Jelka Masin-Spasovska, C.J.C. Jones, Marc E. De Broe, Saso Gelev, Tony Freemont, Maggie Gill, Isabel Webster, Goce Spasovski, and Aleksandar Sikole
- Subjects
Male ,medicine.medical_specialty ,medicine.drug_class ,medicine.medical_treatment ,Urology ,chemistry.chemical_element ,Phosphates ,Ilium ,Calcitriol ,Lanthanum ,Renal Dialysis ,Internal medicine ,medicine ,Humans ,Renal osteodystrophy ,Dialysis ,Aged ,Calcifediol ,Chronic Kidney Disease-Mineral and Bone Disorder ,Transplantation ,business.industry ,Phosphorus ,Middle Aged ,medicine.disease ,Alkaline Phosphatase ,Phosphate binder ,Lanthanum carbonate ,Endocrinology ,Treatment Outcome ,chemistry ,Nephrology ,Parathyroid Hormone ,Toxicity ,Kidney Failure, Chronic ,Calcium ,Female ,Hemodialysis ,business ,Biomarkers ,Kidney disease ,medicine.drug ,Follow-Up Studies - Abstract
Background. Lanthanum carbonate (LC) has been proposed as a new phosphate binder. Presented here are the results from one centre that participated in a multicentre trial to assess the effect of treatment with LC and calcium carbonate (CC) on the evolution of renal osteodystrophy in dialysis patients. Bone biopsies were performed at baseline, after 1 year of treatment and after a further 2-year follow-up period to assess the lanthanum concentration in bone and plasma. Methods. Twenty new dialysis patients were randomized to receive LC (median dose 1250 mg) for 1 year (n ¼ 10), followed by 2 years of CC treatment or CC (n ¼ 10) during the whole study period (3 years). Results. After 36 weeks of treatment, steady state was reached with plasma lanthanum levels varying around 0.6 ng/ml. Six weeks after cessation of 1 year of treatment, the plasma lanthanum levels declined to a value of 0.17 � 0.12 ng/ml (P < 0.05) and after 2 years to 0.09 � 0.03 ng/ml. Plasma and bone lanthanum levels did not correlate with the average lanthanum dose at any time point. The mean bone concentration in patients receiving LC increased from 0.05 � 0.03 to 2.3 � 1.6mg/g (P < 0.05) after 1 year and slightly decreased at the end of the study to 1.9 � 1.6mg/g (P < 0.05). Conclusions. Bone deposition after 1 year of treatment with LC is low (highest concentration: 5.5mg/g). There is a slow release of lanthanum from its bone deposits 2 years after the discontinuation of the treatment and no association with aluminium-like bone toxicity.
- Published
- 2006
216. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis
- Author
-
An R.J. Bervoets, Marc E. De Broe, Geert Dams, Geert J. Behets, Ninoslav Ivanovski, Marie‐M. Couttenye, Goce Spasovski, A. Sikole, and Patrick C. D'Haese
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Population ,Renal Dialysis ,Risk Factors ,Internal medicine ,medicine ,Prevalence ,Outpatient clinic ,Humans ,Renal osteodystrophy ,Osteodystrophy ,Prospective Studies ,education ,Dialysis ,Aged ,Chronic Kidney Disease-Mineral and Bone Disorder ,Transplantation ,Osteomalacia ,education.field_of_study ,business.industry ,Middle Aged ,medicine.disease ,Republic of North Macedonia ,Surgery ,Logistic Models ,Nephrology ,Creatinine ,Kidney Failure, Chronic ,Female ,Hemodialysis ,Bone Remodeling ,business ,Kidney disease - Abstract
Background During the last few years the spectrum of renal osteodystrophy (ROD) in dialysis patients has been studied thoroughly and the prevalence of the various types of ROD has changed considerably. Whereas until a decade ago most patients presented with secondary hyperparathyroidism (HPTH), adynamic bone (ABD) has become the most common lesion within the dialysis population over the last few years. Much less is known about the spectrum of ROD in end-stage renal failure (ESRF) patients not yet on dialysis. Methods Transiliac bone biopsies were taken in an unselected group of 84 ESRF patients (44 male, age 54+/-12 years) before enrolment in a dialysis programme. All patients were recruited within a time period of 10 months from various centres (n=18) in Macedonia. Calcium carbonate was the only prescribed medication in patients followed up by the outpatient clinic. Results HPTH was found in only 9% of the patients, whilst ABD appeared to be the most frequent renal bone disease as it was observed in 23% of the cases next to normal bone (38%). A relatively high number of patients (n=10; 12%) fulfilled the criteria of osteomalacia (OM). Mixed osteodystrophy (MX) was diagnosed in 18% of the subjects. There was no significant difference between groups in age, creatinine, or serum and bone strontium and aluminium levels. Patient characteristics associated with ABD included male gender and diabetes, whilst OM was associated with older age (>58 years). Conclusions In an unselected population of ESRF patients already, 62% of them have an abnormal bone histology. ABD is the most prevalent type of ROD in this population. In the absence of aluminium or strontium accumulation the relatively high prevalence of a low bone turnover as expressed by either normal bone or ABD and OM is striking.
- Published
- 2003
217. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients
- Author
-
Katica Zafirovska, An R.J. Bervoets, Patrick C. D'Haese, Geert Dams, Marc E. De Broe, Goce Spasovski, Viviane Van Hoof, Geert J. Behets, and Momir Polenakovic
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,Population ,Osteocalcin ,Urology ,Parathyroid hormone ,urologic and male genital diseases ,Sensitivity and Specificity ,Bone and Bones ,Bone remodeling ,Diagnosis, Differential ,Renal Dialysis ,medicine ,Humans ,Renal osteodystrophy ,education ,Biochemical markers ,Aged ,Chronic Kidney Disease-Mineral and Bone Disorder ,education.field_of_study ,biology ,business.industry ,Middle Aged ,medicine.disease ,Alkaline Phosphatase ,ROC Curve ,Nephrology ,Parathyroid Hormone ,biology.protein ,Kidney Failure, Chronic ,Calcium ,Female ,Complication ,business ,Biomarkers ,Kidney disease - Abstract
Various biochemical markers have been evaluated in dialysis patients for the diagnosis of renal osteodystrophy (ROD). However, their value in predialysis patients with end-stage renal failure (ESRF) is not yet clear.Bone histomorphometric evaluation was performed and biochemical markers of bone turnover were determined in serum of an unselected predialysis ESRF population (N = 84).Significant (P0.005) differences between the five groups with ROD (ie, normal bone [N = 32], adynamic bone [ABD; N = 19], hyperparathyroidism [N = 8], osteomalacia [OM; N = 10], and mixed lesion [N = 15]) were noted for intact parathyroid hormone, total (TAP) and bone alkaline phosphatase (BAP), osteocalcin (OC), and serum calcium levels. Serum creatinine and (deoxy)pyridinoline levels did not differ between groups. For the diagnosis of ABD, an OC level of 41 microg/L or less (or =7.0 nmol/L) had a sensitivity of 83% and specificity of 67%. The positive predictive value (PPV) for the population under study was 47%. The combination of an OC level of 41 ng/L or less (or =7.0 nmol/L) with a BAP level of 23 U/L or less increased the sensitivity, specificity, and PPV to 72%, 89%, and 77%, respectively. ABD and normal bone taken as one group could be detected best by a BAP level of 25 U/L or less and TAP level of 84 U/L or less, showing sensitivities of 72% and 88% and specificities of 76% and 60%, corresponding with PPVs of 89% and 85%, respectively. In the absence of aluminum or strontium exposure, serum calcium level was found to be a useful index for the diagnosis of OM.OC, TAP, BAP, and serum calcium levels are useful in the diagnosis of ABD, normal bone, and OM in predialysis patients with ESRF.
- Published
- 2003
218. Can we decrease organ trafficking in the Balkans?
- Author
-
Goce Spasovski
- Subjects
Gerontology ,Transplantation ,medicine.medical_specialty ,business.industry ,medicine ,Directed Tissue Donation ,Resource allocation ,Organ Trafficking ,Intensive care medicine ,business ,Organ transplantation - Published
- 2011
219. Is combined calcium/magnesium phosphate binder really noninferior to sevelamer hydrochloride?
- Author
-
Goce Spasovski and Raymond Vanholder
- Subjects
Transplantation ,medicine.medical_specialty ,Endocrinology ,Nephrology ,business.industry ,Calcium magnesium phosphate ,Internal medicine ,medicine ,Sevelamer Hydrochloride ,medicine.disease ,business ,Kidney disease - Published
- 2011
220. Use of advanced age donors in living renal transplantation--is it justified?
- Author
-
Cakalaroski K, Zivko Popov, J. Paneva-Masin, Goce Spasovski, Ninoslav Ivanovski, Lj Stojkovski, and P. Kolevski
- Subjects
Adult ,Aged, 80 and over ,Transplantation ,medicine.medical_specialty ,business.industry ,Graft Survival ,Age Factors ,Middle Aged ,Kidney Transplantation ,Surgery ,Survival Rate ,Creatinine ,Living Donors ,Medicine ,Humans ,business ,Biomarkers ,Aged - Published
- 2001
221. Effect of Lowering Dialysate Calcium on Bone and Mineral Parameters Related to Adynamic Bone Disease
- Author
-
Raymond Vanholder and Goce Spasovski
- Subjects
medicine.medical_specialty ,Nephrology ,business.industry ,Urology ,medicine ,Adynamic bone disease ,Hematology ,business ,Dialysate calcium ,Surgery - Published
- 2007
222. Living-Unrelated (Paid) Renal Transplantation—Ten Years Later
- Author
-
K Zafirovska, J Masin, Zivko Popov, Cakalaroski K, Goce Spasovski, and Ninoslav Ivanovski
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Cirrhosis ,Adolescent ,Urinary system ,Population ,India ,Renal function ,Donor Selection ,Nephropathy ,Postoperative Complications ,Nepal ,Hypertensive Nephropathy ,Living Donors ,medicine ,Humans ,Child ,education ,Transplantation ,education.field_of_study ,business.industry ,Graft Survival ,Middle Aged ,Hepatitis B ,medicine.disease ,Kidney Transplantation ,Republic of North Macedonia ,Survival Analysis ,Surgery ,Treatment Outcome ,Fees and Charges ,Female ,business - Abstract
Due to the increase of organ shortage and still inadequate development of cadaver transplantation, many end-stage patients from the Balkan region travel mostly to India to buy a kidney. Despite all the ethical dilemmas and discussions, organ sales is present nowdays in Third-World countries. Sixteen patients (13 from Macedonia and 3 from Kosovo, SCG) were observed clinically during a period of 10 years. Recipients of mean age 36.5 years (range 10 to 58) displayed the following underlying diseases: chronic glomerulonephritis (n = 5), urethral valves with reflux (n = 2), ADPKD (n = 1), hypertensive nephropathy (n = 4), lithiasis (n = 1), and unknown cause of ESRD (n = 3). The donor population was young (22 to 29 years). Most patient records did not include data on HLA, cross-match, MLC, kind of surgery, or usual pretransplant workup. The immunosuppressive protocol included CyA, PRED, and AZA or MMF. All transplanted patients were followed on an outpatient basis in our department; patients with complications were hospitalized. The 1, 3, 5, and 10 year Kaplan Meier graft survival rates were 78.6%, 50.2%, 33.3%, and 18.8%, respectively. Seven patients were lost (43.7%), two during the first month after transplantation, two at the end of the first year, and three at 5, 6, and 8 years thereafter. The main reasons for death were severe pulmonary infections with sepsis, hepatitis B with liver cirrhosis, Kala Azar, CMV, and cancer of the colon. Five grafts were lost due to repeated rejection episodes and chronic graft nephropathy. The last three cases remained with good renal function and actual serum creatinine values of 135 +/- 9. In view of this experience, the authors cannot recommend this type of transplantation, not only from the ethical point of view, but also from frequent medical and surgical complications which are sometimes life threatening.
- Published
- 2005
223. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation
- Author
-
Ninoslav Ivanovski, Goce Spasovski, Cakalaroski K, J. Paneva-Masin, Aleksandar Sikole, P. Kolevski, and Zivko Popov
- Subjects
Graft Rejection ,Daclizumab ,Time Factors ,medicine.drug_class ,Basiliximab ,Recombinant Fusion Proteins ,medicine.medical_treatment ,Drug Resistance ,Antibodies, Monoclonal, Humanized ,Monoclonal antibody ,Azathioprine ,Living Donors ,medicine ,Humans ,Retrospective Studies ,Transplantation ,Kidney ,business.industry ,Antibodies, Monoclonal ,Interleukin ,Receptors, Interleukin-2 ,Immunotherapy ,Mycophenolic Acid ,Kidney Transplantation ,medicine.anatomical_structure ,Cytokine ,Immunoglobulin G ,Immunology ,Cyclosporine ,Drug Therapy, Combination ,Steroids ,Surgery ,business ,Immunosuppressive Agents ,Follow-Up Studies ,medicine.drug - Published
- 2001
224. Renal transplantation - clinical studies - 1
- Author
-
Francesca Sidoti, V. Jha, Massimiliano Bergallo, Beom Seok Kim, Jerzy Chudek, Hyunwook Kim, Petar Kes, Nadezda Babenko, Diana C. Grootendorst, Ahmed A. Shokeir, Mohammad Mahdi Sagheb, Erkan Demir, Mohamed A. Ali, Joon Heun Jeong, Malihe Layeghian Javan, Sonja Dzikova, Mariangela Leal Cherchiglia, Reza Hekmat, Maria Emilia Ferreira, Franca Giacchino, Z. Jabbar, M.R. Alam, S.Y. Tan, Oestein Bentdal, Ralf Schindler, Anna Casula, Natalia Polanco, T.C. Keng, Jae Ho Choi, P. Fraile, C. Randoux, Ho Yung Lee, Federica Neve Vigotti, Fatemeh Pour-Reza Gholi, J.M. Tabernero, R.M.V. Ree, Inara Adamsone, Marc A. Seelen, B. Sis, K.S. Famulski, W.Y. Kong, Jelka Masin-Spasovska, R.O.B. Gans, Juan Vanegas, Eric Lechevallier, J. vd Born, Mustafa Balal, Antonino Catalano, Jung Tak Park, E. Kerezsy, Hallvard Holdaas, Jean-Pierre Grünfeld, Chantal Gautreau, Ljupco Lekovski, Maria Elena Terlizzi, Goce Spasovski, Efat Razeghi, Filógenes Aguirre, David Ansell, Zoubeir Skalli, Jaap J. Homan van der Heide, Jong Oh Lee, S. Bunnag, Annie Lahoche, Caroline Suberbielle-Boissel, Magdalena Szotowska, Dominique Charron, Ronald P. Stolk, Valérie Moal, Ana Paula Alvares, Dirk De Bacquer, Yip Boon Chong, Thomas F. Mueller, Budiman David, Dorien M. Zelle, Eva Gavela, I. Ursuleac, Christiane Mousson, Paul Roderick, Wha Rhim Lee, Bulent Tokgoz, Pietro Lampertico, Mehmet Sikgenc, Pavel Jindra, Gerardo Oliveira, Dominique Nochy, Vahid Pourfarziani, Charles R.V. Tomson, Andrzej Wiecek, Kristian Heldal, François Provôt, Wilfried Gwinner, Sharnaz Shahidi, M. Rathi, Jerome Verine, Arbey Aristizabal, Joana Santos, François Glowacki, Ana Maria Manzione, Raymond Vanholder, Philipp Halloran, S.H. Teo, Luís Coentrão, Asia Khanam, Pedram Ahmadpour, Udaya Udayaraj, Hermann Haller, Ghanbarali Raeesjalali, Eun Young Kim, A.E. Heng, Sandro Feriozzi, Myoung Soo Kim, Sun Young Park, P.F. Halloran, Patrick Peeters, Joao Andrade, Tomas Vanecek, Jana Nemcova, Carlos Guzman, Hakim Hamzaoui, Dong Ryeol Lee, Ninoslav Ivanovski, María M. Morales-Suárez-Varela, Harry Abadia, François Buissou, M. Buchler, M. Mengel, Marie Frimat, Wael Nassar, Lama Barakat, P.K. Agarwal, Denis Glotz, I. Sinescu, Willy Aaseboe, Christopher Dudley, L.P. Tan, Karsten Midtvedt, Mohamed Ghonein, Mauro Viganò, Saman Nikeghbalian, Roy Calne, Giovanna Lunghi, J.J. Homan vd Heide, Mahmoud El-Baz, F. Bayle, Ljubica Bubic-Filipi, Anders Hartmann, Alvaro Mena, H.U. Rashid, Chew Ming Wong, Francisco de Assis Acurcio, Pieter Evenepoel, Fabrizio Fop, Khadidheh Makhdomi, Maryam Sharifian, M.S. Islam, Amado Andrés, Bassam Saeed, Zahra Javadi, Lech Cierpka, Dmitry Babarykin, M. Salahuddin, Ivana Jurić, Kathleen Claes, Saime Paydas, E. Thervet, Carmen Lefaucheur, Abeed Pall, Waleska Teixeira Caiaffa, Y. Lebranchu, Gerjan Navis, Dong Ki Kim, Olga Randone, Zivko Popov, Sara Astegiano, Francis Verbeke, G. Einecke, Yu Seun Kim, Stephan J. L. Bakker, Elaine Leandro Machado, Ondrej Hes, Stanislav Kirillov, Henryk Karkoszka, Yvon Berland, G.J. Navis, Christian Coulange, Tatyana Cheprasova, Anke Schwarz, T. Frouget, Fergus Caskey, Seyed Ali Malek-Hosseini, Maria Messina, Beti Dejanova, Elisabetta Mezza, Esther González, H. Rahman, D. Yrrell, Arsen Abovyan, Murat Hayri Sipahioglu, Mohamed A. Bakr, I. Alexiu, Hassan Argani, Cristina Alina Bucsa, S.J.L. Bakker, Hakima Rhou, Cristina Costa, Manuel Pestana, Tarek M. Abbas, Rabia Bayahia, Hyae Ju Oh, Dave Collett, Antonio Lavacca, Motaz Obeidat, Laurent Daniel, Intissar Haddiya, Ana Ávila, Véronique Frémeaux-Bacchi, Eghlim Nemati, Ahad Eshraghian, Tomas Reischig, J. Reeve, D. Tacu, Wim Van Biesen, H. Mazouz, Susana Sampaio, Essam Lotfy, Nadine Zoephel, Boshra Hassanzamani, Yann Neuzillet, Cengiz Utas, Daniele A.C. Szuster, P. Macintyre, P. Halloran, H.S. Kohli, Rafał Zwiech, Anna Varberg Reisæter, Sima Abediazar, Malaka Yehya Fouad, Giuseppe Montagnino, Dinanda de Jager, Eli Iola Gurgel Andrade, P.G. Cosmes, Torbjørn Leivestad, I. Etienne, Roland Hetzer, Byng Chang Kim, Kyu Hun Choi, K.L. Gupta, Ashraf Donia, Rijk O. B. Gans, Jan P. Schouten, Graham A. Stewart, Adel Ghorab, V.G. Bernalt, Ali Bahador, Mohsen Nafar, L. Pallardó, Torbjoern Leivestad, Hamid Tayebi Khosroshahi, Mohammad Kazem Tarzamni, Juliana Álvares, Asunción Sancho, Enrique Morales, Piergiorgio Messa, Nassim Kamar, Behzad Einollahi, Ibrahim Barghouth, Isabel Cristina Gomes, Ahmed F. Hamdy, W.J.V. Son, Gustavo Zuluaga, Fadoua Bouabid, S Behzadi, Giuseppe Paolo Segoloni, Marc Hazzan, Mi Young Jeon, Rutger M. van Ree, F. Allano, Alan Zokoev, O. Toupance, G. Touchard, Urszula Siekiera, JoséF. Crespo, Gary S. Hill, Hans Lehmkuhl, Michael Kaabak, Erik Heyerdahl Stroem, Amir M Elokely, Mohamed A. Ghoneim, José M. Morales, Valerie A. Luyckx, Nikolina Bašić-Jukić, Tae Ik Chang, Vinay Sakhuja, Mohamed Shamrouk, Oscar Leiva, Yoav Ben-Shlomo, Jorge González, Yong Hun Shin, Dirk Kuypers, Catarina Carvalho, N. Simforoosh, Manuela Bustorff, Cibele C Comini, Narges Sobhani, Heshmatollah Salahi, D. Glotz, Jae Hyun Chang, Saffa Elawad, Adriana Aroldi, Mahboob Lessan-Pezeshki, Ulrich Frei, Loubna Benamar, Jamshid Roozbeh, Gordana Petrusevska, Rafail Rozental, Michael Mengel, Ana Hernández, Walter Angel, Yasar Sertdemir, Tae Hyun Yoo, Catalina Ocampo, Manuel Praga, B. Moulin, Roberta Giraudi, Ilaria Napoletano, Mirko Bouda, U. Erken, Feliks Kacprzyk, Soo Kun Lim, Chiara Merlino, Winston W. Bakker, G.S. Jhangri, Joong Kyung Kim, Daniel Kobewka, Maurizio Ferro, Diana Amerika, Heshmatollah Shahbazian, S.A. Khan, Oktay Oymak, Vladislav Treska, Christina Doerje, Naima Ouzeddoun, D. Kayser, Franco Bonello, Nariman Nezami, Catalina Velez, Bert Bammens, Steven Van Laecke, Yves Vanrenterghem, Young Ki Son, J.P Rerolle, Figen Binokay, Aydin Unal, P. Martín, G. Tognarelli, Rachel Johnson, B. Hurault de Ligny, Cemal Kurt, Jan A. Krikken, Ali Ghafari, Shin Wook Kang, Hussein Sheashaa, Dong Hyung Lee, Arnaud Lionet, Mohammad Hossein Nourbala, Inese Folkmane, Carlo Massimetti, Maria Teresa Muratore, Rania Derani, Fatima Zahra Berkchi, Rossana Cavallo, Taeibi Khosroshahi, C. Dobrea, Ehab W. Wafa, Soon Il Kim, Christian Noel, Eduardo Gutiérrez, Theo Borghuis, Feridun Kavuncuoglu, Thomas Rath, and Rafael Díaz
- Subjects
Transplantation ,medicine.medical_specialty ,Nephrology ,business.industry ,Medicine ,business ,Surgery - Published
- 2009
225. Cardiovascular complications - 1
- Author
-
Yasuharu Tohara, Noriaki Kurita, Xiaohong Fan, Mislav Radic, Ionut Nistor, Teresa Adragão, Eiji Yamauchi, Seung-Jung Kim, Mototsugu Tanaka, Koji Okino, Masaaki Inaba, Palaniappan Saravanan, Guangli Ge, Rodoljub Markovic, Fani Dogramatzi, Minoru Furuta, Hye Eun Yoon, Mohit Lathar, Veselinka Djurkovic, Ibrahim Ozdogru, W.V. Kuijk, Rajan K. Patel, Eberhard Ritz, Shahrzad Ossareh, Tadao Akizawa, Toshiko Tokoro, Byung Soo Kim, Friedo W. Dekker, Shinsuke Yamada, Georgios Eftratiadis, Abdel-Bassit El-Shaarawy, Jeong-Min Lee, Erzsebet Fodor, Xiaoyun Wang, Takahiro Kuragano, Kiyoshi Matsuoka, Naobumi Mise, Bruce L. Riser, Yang Sun, Masato Nishimura, Patricia Branco, Marina Toutouza, Elena Banfi, Diana Yonova, Tamás Szabó, Aikaterini Papagianni, Noriyuki Kato, Ping Jiang, Birsel Unal, Jianming Hu, Xiaoyong Yu, Tokuichiro Sugimoto, Apostolos Tsiandoulas, Alan G. Jardine, Daisuke Sanada, Hideyuki Yasuno, Aritoshi Kida, Jyotsana Sen, Ana Pires, Steva Pljesa, Yuri Tanaka, Kyu Bok Choi, Mari Nakamura, Nobuhiko Joki, Meng Zhang, Georgios Niavis, Sehnaz A. Ertekin, M. Aquarius, Masaya Nishida, Mustafa Duran, András Tislér, P.M. Ghezzi, Ljiljana Komadina, Aytül Noyan, Ho Cheol Song, Zsófia K. Németh, Chie Shiraki, Maria Luisa Biondi, Anna-Maria Belechri, Paul Gusbeth-Tatomir, Goce Spasovski, Aikaterini Petrohilou, Maria Protopappa, Hiroaki Ogata, Austin G. Stack, Veselka Stojnova, Kutay Taşdemir, Joaquim Bordalo, Shunli Tian, Limeng Chen, Maurizio Gallieni, Takao Uchida, Loubna Benamar, Hiroyuki Kobayashi, Milenka Sain, Rui Castro, Gavin Freeman, Antoinette Nealon, Luminita Voroneanu, Masayoshi Nanami, Hiroyasu Ishikawa, Mikos Szathmari, Xuemei Li, Jun Qian, Hiroki Niikura, Shinji Tanaka, Hiroki Hase, Alexander G. Logan, Young Ok Kim, Hong Xu, Christoph Wanner, Dimitrios Memmos, Bin Sun, Dimitrios Petras, Vili Amitov, Kiyoshi Maekawa, Aristeidis Stavroulopoulos, György Deák, Takeshi Nakanishi, Tetsuya Hashimoto, Yukiko Hasuike, Aicha Radoui, Aysun Karabay Bayazit, Hiroshi Nonoguchi, Mihai Onofriescu, Karl Winkler, Simeon Antonov, Eiji Ishimura, Aleksandar Sikole, Takahiro Nishi, Satoru Yamazaki, Alan Jardine, Yasuo Imanishi, A. Luik, Phani Markou, Oktay Oymak, Naima Ouzeddoun, Jozsef Egresits, Gulinuer Muteliefu, Li-Tao Cheng, Ming Zeng, Yoshinaga Otaki, Yoshihiko Imamura, Ashraf El-Saeed, Simona Hogas, Claudiu Cusai, Ivo Jelicic, Yasushi Shimonaka, Mehman Aghayev, Vera Krane, Jia Liu, Mike Venning, Gulsah Seydaoglu, Takeshi Miyairi, Sumio Miura, Cengiz Utas, Mario Cozzolino, Saskia le Cessie, Liangying Gan, Aygul Karabayeva, Maria Nedevska, Xuewang Li, Kyun Il Yoon, Catherine Wall, Dong Ryeol Ryu, Intissar Haddiya, Ali Anarat, Kaori Sato, Toshimitsu Niwa, Soeren D. Ladefoged, Kenji Arizono, Ana Oliveira, Ioannis T. Papadakis, Aysa Nimgirova, Ningning Wang, Georgios Efstratiadis, Dimitrios Kirmizis, Atsushi Enomoto, Diego Brancaccio, Kyriaki Stamatellou, Nicola Johnston, A. Serra, Jianling Tao, L. Corazza, Ljiljana Lambic, Saso Gelev, Ryo Imai, Hirotaka Suzuki, Yoshiki Nishizawa, Ivan Kayukov, Rabia Bayahia, Joakim Cordtz, Nozomu Hosaka, Michael Timofeyev, Slavco Tosev, Changying Xing, Henry J. Dargie, Dragan Ljutic, Taha El Hadj Othmane, Pascal Meier, István Kiss, Murat Hayri Sipahioglu, Daryoush Saedi, Yoshio Matsushita, Hyeon Hwa Jeong, Katsukiyo Ito, Hoang Nguyen, Keiko Sai, Athanasia Tsiriga, Noriyuki Iwamoto, Najoua Zbiti, Adrian Covic, Vedran Kovacic, Hari Krishan Aggarwal, Xiangbao Yu, Anoosha Alaee, Serban Ardeleanu, Neil Davidson, Senji Okuno, Yasunori Takahashi, Rie Kitamura, Sijun Li, Duk Hee Kang, Maria Pangalou, Ehsan Hajiaboli, Jinghua Yang, Zijuan Zhou, Ashot Essaian, Yong Zeng, Christiane Drechsler, Ikutaro Kigawa, Masahide Mizobuchi, Aydin Unal, Euy Jin Choi, Ioannis Kakavas, Patrick B. Mark, Mi Jung Shin, Konstantinos Barboutis, Tao Wang, P.G. Bolasco, Toshihiko Ono, B. Fekete, J. Swaanenburg, Mei Wang, Josipa Radic, Bulent Tokgoz, Aphroditi Valtopoulou, Eriko Kinugasa, Zohra Tumur, Raluca Caliniuc, Winfried März, Yong Kyun Kim, Hakima Rhou, Evangelia Koutoupa, Efstathios Alexopoulos, Carmen Volovat, Alexandr Yenkun, Janos Nemcsik, and Xiufen Zhao
- Subjects
Transplantation ,medicine.medical_specialty ,Nephrology ,business.industry ,medicine ,Intensive care medicine ,business - Published
- 2009
226. Renal transplantation - clinical studies - 3
- Author
-
J M Campistol, Galina Severova-Andreevska, Asiq Ali, Ferruccio Conte, Miklos Z. Molnar, Yogesh N.V. Reddy, Éva Toronyi, Zoltán Kiss, Florian Swoboda, Maristela Bohlke, Upendra Singh, Stefan G. Tullius, Juan Bravo, Luisa Berardinelli, P. de Jong, Yoshitaka Isaka, Ali Bakran, Ali Ghafari, Amir Kameli, Walcy Rosolia Teodoro, Marcelo Sampaio, Paula C.B.C. Fernandes, Niels Olsen Saraiva Camara, Keri Roberts, Piergiorgio Messa, Varun Sundaram, Lale Jafari, Luiz Felipe Santos Gonçalves, Constantinos Deltas, Claudia Sommerer, Saber Shamspour, Yasar Caliskan, Laleh Jafari, Mohamad Ghasemi Rad, Suheyla Apaydin, Anett Lindner, Sofia Zarraga, Saravanan Sundarajan, Katharina Rahn, Adam Remport, Daniela C.O. Santos, Manuela Almeida, Ewa Ignacak, Ronaldo M. Esmeraldo, Mohammad Ghasemi-rad, Lluis Guirado, Halil Yazici, Yong Cho, M.F.G. Rocha, El-Metwally El-Shehawy, El-Metwaly El-Shahaway, R.T. Gansevoort, Andras Szentkiralyi, Marta Novak, Ramyasuda Swaminathan, Kélcia Rosana da Silva Quadros, Syed Atif Mohiuddin, Rashad Hassan, Sandra Mueller-Krebs, Marina Varga, Amgad E. El-Agroudy, Alpar S. Lazar, Christoph Wanner, Nilgun Aysuna, D. Dadhania, Dino Martini, Enyu Imai, Susana Pereira, Mohamed A. Sobh, Neda Poommipanit, Georgi Abraham, Masahiro Nishikawa, Maria E. Czira, Yoko Yamauchi, Jitka Stepankova, Muzaffer Sariyar, Nurhan Seyahi, Slobodan Antov, J.J. Homan van der Heide, Thangamani Muthukumar, Jeno Járay, Ayako Okuno, Rezzan Ataman, Karla Lais Pêgas, Ondrej Viklicky, Luciana Ghio, Naohiko Fujii, Maciej Drozdz, Takahiro Akiyama, Mehmet Riza Altiparmak, Khalid Mahmoud, L. Dias, Hirotaka Tanaka, Ana Cristina Matos, David Ansell, Naotsugu Ichimaru, Barbara Grandtnerova, A. Henriques, Arvind Ponnusamy, Szilárd Török, S. Seshan, Luiz Antonio Ribeiro de Moura, Shaker Salari, Claudia M. C. Oliveira, Michael J. Mihatsch, Kai Lopau, Lawrence Solomon, Claudio Beretta, Maria Jesus Martinez de Osaba, Robert Meyer, Mohamed A. Ghoneim, Lisoneide Terhorst, Sylvie Dusilová-Sulková, Mehmet Sukru Sever, Janka Slatinska, Lynsey Webb, Martin Zeier, Maria Ramos Cebrian, Ambadi Ramachandran, Zahra Sabahi, Helen Tzanatos, Rudolf P. Wüthrich, W. van Oeveren, Leonidio Dias, Kazuharu Uchida, Gilles Straub, Ali Taghizadeh, Klemens Budde, Ahmed F. Hamdy, Alaattin Yildiz, R. Almeida, M. Suthanthiran, S.J.L. Bakker, Rezso Zoller, Nagy Abd El-Hady, S. Pedroso, Yuvaram N.V. Reddy, Numan Gorgulu, Alvaro Pacheco-Silva, John Bankart, Ninoslav Ivanovski, Joao Evangelista, Luis Antonio Ribeiro Moura, Wagner V. Dominguez, Mohamed Salem, Sagrario Garcia, Ehab W. Wafa, Günther F.L. Hofbauer, Gentil Alves-Filho, Luis Oliveira, Olga Krizanova, Kamil Serdengecti, Gyula Végso, Raquel Franco Santos, Marcela Burgelova, Anna Casula, R. Chmel, Khadijeh Makhdoomi, P. Santos, Berna Yelken, Federico Oppenheimer, A. Cabrita, Cleonice Giovanini Alves da Silva, Sameh Hana, Meral Tasan, Piegiorgio Messa, Fergus Caskey, Antonio Henriques, Stela Scaglioni Marini, Irene L. Noronha, Eve Chowaniec, Yoshiaki Inui, Katalin Földes, Hana Berdnikova, Franklin Correa Barcellos, Mauro Raiteri, Ashley Irish, Katalin Fornadi, R. Ding, Suphamai Bunnapradist, Aydin Turkmen, Goce Spasovski, Niels Olsen Camara, Takayuki Hamano, Maria Pia Rastaldi, M. Teixeira, Andreas L. Serra, Maryam Zare, Kunio Morozumi, Istvan Mucsi, Camilo Reuber, Muhammed Ahmed, Miguel A. Gentil, Asami Takeda, Ahmed Akl, Amani Mostafa, Salih Pekmezci, Katarzyna Janda, Daniel Vedlich, Maria Luisa M.B. Oliveira, Farideh Bagheri, Francisco José Veríssimo Veronese, Petr Bubenicek, Ayman F. Refaie, La-Salete Martins, Ljubco Lekovski, Mozar Suzigan de Almeida, Matthias Schaier, C. Snopkowski, Sayeed Malek, Silvio Sandrini, Elizabeth Lamerton, Roberto Ceratti Manfro, Christoforos Stavrou, Ricardo Sesso, Fabio Massimo Ulivieri, Shiro Takahara, Hans-H. Neumayer, Antonio Cabrita, Carlo Alfieri, Maria Claudia Irigoyen, Alina Betkowska Prokop, Andrea Dunai, Virna Nowotny Carpio, Devendra Agarwal, Amani Moustafa, Andrzej Krasniak, Hidehumi Kishikawa, Steven Gabardi, Hiromi Rakugi, Dariusz Aksamit, Anil Chandraker, Janet Hagerty, Andreas Soloukides, Eduardo Bronzatto, Hugo Ludovico Martins, Hany Adel, Anke Godemann, Marilda Mazzali, Irena Rambabova-Busletic, Marina Balderacchi, Isao Matsui, Hasan Taşçi, Roberto Marcen, Maria Isabel Albano Edelweiss, Brigida Brezzi, H. van Goor, Rafael Hissé Gomes, Petra Glander, Yasuji Ichikawa, Valsamakis Hadjiconstantinou, Ayman Maher, Lutz Liefeldt, Zivko Popov, Lars E. French, Charles R.V. Tomson, Diego Morais Gomes, Ahmed A. Shokeir, E.E. Minetti, R. Seca, Carolina Rech, Władysław Sułowicz, Thomas Ben, Jose-Vicente Torregrosa, F. Nauta, Carlos Bergua, Paulo Santos, Jelka Masin-Spasovska, Evlyn Eickhoff, Dimitrios-Anestis Moutzouris, Donata Cresseri, and Kodo Tomida
- Subjects
Transplantation ,medicine.medical_specialty ,Nephrology ,business.industry ,medicine ,business ,Surgery - Published
- 2009
227. An established tradition--the Eighth Congress of the Balkan Association of Nephrology, Dialysis, Transplantation and Artificial Organs (BANTAO) Belgrade, Serbia, 16-19 September 2007
- Author
-
Milan Radovic, Goce Spasovski, and Momir Polenakovic
- Subjects
Nephrology ,Transplantation ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Physiology ,Congress Report ,Cultural phenomenon ,Internal medicine specialists ,Family medicine ,Internal medicine ,medicine ,Paediatric nephrology ,business ,Dialysis - Abstract
The 8th Congress of the Balkan Association of Nephrology, Dialysis, Transplantation and Artificial Organs (BANTAO) took place, from 16 to 19 September 2007, in Belgrade, Serbia. After the seven previous successful congresses and this latest one in Belgrade, we are convinced that BANTAO has become firmly established as a professional and cultural phenomenon. Born in Ohrid 1993 and followed by the congresses in Varna (1995), Struga (1997), Belgrade (1998), Izmir (1999), Thessaloniki (2001), Varna (2003) and Ohrid (2005), the Congress in Belgrade showed that the BANTAO idea can be considered as a true marker of our regional communication and collaboration, and as the major forum of Balkan nephrologists, with around 500 participants. Balkan nephrologists have recognized and taken advantage of working in a world without political boundaries; we also have the support of the European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) and the International Society of Nephrology (ISN), which comes in recognition of our efforts and achievements in attaining the best results for our patients on local and regional levels. The Congress was attended by 456 physicians (nephrologists, nephrology fellows, transplant physicians, cardiologists, internal medicine specialists) from the Balkans, Europe and Asia. In addition to the support of the ERA/EDTA and ISN/COMGAN, the Congress was held under the patronage of their Royal Highnesses Prince Alexander of Serbia and Princess Katherine. In the fields of epidemiology of renal disease, clinical and paediatric nephrology, haemoand peritoneal dialysis, kidney transplantation and apheresis, there were 60 invited guest lecturers and 47 oral and 137 poster presentations. The programme included four educational symposia, two ERA/EDTA courses, three Balkan symposia, six round tables (one ISN/COMGAN) and six keynote lectures; many distinguished nephrologists presented the latest achievements in different fields of nephrology. Importantly, for the
- Published
- 2007
228. The dream is now a reality—The seventh Congress of the Balkan Association of Nephrology, Dialysis, Transplantation and Artificial Organs (BANTAO) Ohrid, Republic of Macedonia, 8–11 September 2005
- Author
-
Goce Spasovski and Momir Polenakovic
- Subjects
Nephrology ,Transplantation ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,media_common.quotation_subject ,Environmental protection ,Family medicine ,Internal medicine ,medicine ,Dream ,business ,Dialysis ,media_common - Published
- 2006
229. LIVING UNRELATED (PAID) RENAL TRANSPLANTATION - TEN YEARS AFTER
- Author
-
J Masin, Ninoslav Ivanovski, K Zafirovska, Koco Cakalaroski, and Goce Spasovski
- Subjects
Transplantation ,Pediatrics ,medicine.medical_specialty ,business.industry ,Medicine ,business - Published
- 2004
230. Could living unrelated renal transplantation ameliorate the actual shortage of organs in the Balkan region?
- Author
-
Zivko Popov, Aleksandar Sikole, J. Masin-Spasovska, Ninoslav Ivanovski, P. Kolevski, I. Rambabova Busljetik, and Goce Spasovski
- Subjects
Transplantation ,medicine.medical_specialty ,business.industry ,Medicine ,Economic shortage ,business ,Intensive care medicine
231. BANTAO journal: A story of ten years
- Author
-
Goce Spasovski, Dimitrios S. Goumenos, Nikolina Bašić-Jukić, Mustafa Arici, and Nada Dimkovic
- Subjects
Nephrology ,Transplantation ,medicine.medical_specialty ,business.industry ,Internal medicine ,Family medicine ,Medicine ,business ,RC31-1245
232. A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients
- Author
-
Patrick C. D'Haese, Alessandro Balducci, Giorgio Coen, Milan Popovic, Sylvie Dusilova Sulkova, Aníbal Ferreira, Llubica Djukanovic, Goce Spasovski, A. Sikole, Waldysaw Sulowicz, Svetlana Pejanovic, Tony Freemont, Nada Dimkovic, Armando Torres, Charles R. Swanepoel, Alastair J. Hutchison, Marc E. De Broe, and Slobodan Curic
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.drug_class ,Urology ,phosphate binder ,Bone and Bones ,Calcium Carbonate ,Phosphates ,Bone remodeling ,osteodystrophy ,Hyperphosphatemia ,chronic renal failure ,Lanthanum ,Renal Dialysis ,Internal medicine ,medicine ,Humans ,open-label study ,Renal osteodystrophy ,Osteodystrophy ,bone histomorphometry ,Aged ,Chronic Kidney Disease-Mineral and Bone Disorder ,Hyperparathyroidism ,Osteomalacia ,business.industry ,Middle Aged ,medicine.disease ,Phosphate binder ,Lanthanum carbonate ,Endocrinology ,Nephrology ,Hypercalcemia ,Kidney Failure, Chronic ,Female ,Hyperparathyroidism, Secondary ,business ,Biomarkers ,medicine.drug - Abstract
A multicenter study on the affects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients. Background Lanthanum carbonate (LC) (Fosrenol™) is a novel new treatment for hyperphosphatemia. In this phase III, open-label study, we compared the effects of LC and calcium carbonate (CC) on the evolution of renal osteodystrophy (ROD) in dialysis patients. Methods Ninety-eight patients were randomized to LC ( N = 49) or CC ( N = 49). Bone biopsies were taken at baseline and after one year of treatment. Acceptable paired biopsies were available for static and dynamic histomorphometry studies in 33 LC and 30CC patients. Blood samples were taken at regular intervals for biochemical analysis and adverse events were monitored. Results LC was well tolerated and serum phosphate levels were well controlled in both treatment groups. The incidence of hypercalcemia was lower in the LC group (6% vs. 49% for CC). At baseline, subtypes of ROD were similarly distributed in both groups, with mixed ROD being most common. At one-year follow-up in the LC group, 5 of 7 patients with baseline low bone turnover (either adynamic bone or osteomalacia), and 4 of 5 patients with baseline hyperparathyroidism, had evolved toward a normalization of their bone turnover. Only one lanthanum-treated patient evolved toward adynamic bone compared with 6 patients in the CC group. In the LC group, the number of patients having either adynamic bone, osteomalacia, or hyperpara decreased overall from 12 (36%) at baseline to 6 (18%), while in the calcium group, the number of patients with these types of ROD increased from 13 (43%) to 16 (53%). Conclusion LC is a poorly absorbed, well-tolerated, and efficient phosphate binder. LC-treated dialysis patients show almost no evolution toward low bone turnover over one year (unlike CC-treated patients), nor do they experience any aluminum-like effects on bone.
233. European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP).
- Author
-
Carmine Zoccali, Daniel Abramowicz, Jorge B Cannata-Andia, Pierre Cochat, Adrian Covic, Kai-Uwe Eckardt, Denis Fouque, Olof Heimburger, Alison McLeod, Elizabeth Lindley, Francesco Locatelli, Goce Spasovski, James Tattersall, Wim Van Biesen, Christopher Wanner, and Raymond Vanholder
- Published
- 2008
- Full Text
- View/download PDF
234. Review on uraemic solutes II Variability in reported concentrations: causes and consequences.
- Author
-
Raymond Vanholder, Nathalie Meert, Eva Schepers, Griet Glorieux, Angel Argiles, Philippe Brunet, Gerald Cohen, Tilman Drüeke, Harald Mischak, Goce Spasovski, Ziad Massy, Joachim Jankowski, and for the European Uremic Toxin Work Group (EUTox)
- Subjects
MANUSCRIPTS ,BIBLIOGRAPHY ,NONBOOK materials ,COPYISTS - Abstract
The aim of this manuscript is to initiate a constructive discussion about deviations in measured concentrations of uraemic solutes; these deviations, if not perceived or handled appropriately, may lead to incorrect interpretations of the pathophysiological role of uraemic solutes and/or to erroneous therapeutic decisions. To come to an objective approach towards this problem, variability analysis of reported concentrations may be of help. Striking outliers should either be discarded or considered together with other values which are more consistent with the majority of reported data. [ABSTRACT FROM AUTHOR]
- Published
- 2007
235. The dream is now a reality—The seventh Congress of the Balkan Association of Nephrology, Dialysis, Transplantation and Artificial Organs (BANTAO) Ohrid, Republic of Macedonia, 8–11 September 2005.
- Author
-
Momir Polenakovic and Goce Spasovski
- Published
- 2006
- Full Text
- View/download PDF
236. Serum Uremic Toxins and Histological Findings of the Blood Vessels in Dialysis Patients
- Author
-
Ministry of Science and Education, R. Macedonia and Goce Spasovski, PI
- Published
- 2010
237. Brain dysfunction in tubular and tubulointerstitial kidney diseases
- Author
-
Viggiano D, Bruchfeld A, Carriazo S, de Donato A, Endlich N, Ferreira AC, Figurek A, Fouque D, Franssen CFM, Giannakou K, Goumenos D, Hoorn EJ, Nitsch D, Arduan AO, Pešić V, Rastenyté D, Soler MJ, Rroji M, Trepiccione F, Unwin RJ, Wagner CA, Wiecek A, Zacchia M, Zoccali C, Capasso G, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)., Viggiano, D, Bruchfeld, A, Carriazo, S, de Donato, A, Endlich, N, Ferreira, Ac, Figurek, A, Fouque, D, Franssen, Cfm, Giannakou, K, Goumenos, D, Hoorn, Ej, Nitsch, D, Arduan, Ao, Pešić, V, Rastenyté, D, Soler, Mj, Rroji, M, Trepiccione, F, Unwin, Rj, Wagner, Ca, Wiecek, A, Zacchia, M, Zoccali, C, Capasso, G, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative, Target)., NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), CarMeN, laboratoire, University of the Study of Campania Luigi Vanvitelli, Karolinska University Hospital [Stockholm], Linköping University (LIU), IIS‑Fundación Jiménez Diaz‑Autonoma University [Madrid, Spain], University of Medicine Greifswald, Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Universität Zürich [Zürich] = University of Zurich (UZH), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), University of Groningen [Groningen], European University of Cyprus, General University Hospital of Patras, Erasmus University Medical Center [Rotterdam] (Erasmus MC), London School of Hygiene and Tropical Medicine (LSHTM), University of Belgrade [Belgrade], Lithuanian University of health Sciences [Kaunas], Vall d’Hebron Research Institute (VHIR), University Hospital Center 'Mother Tereza' [Tirana, Albania] (UHCMT), University College of London [London] (UCL), Medical University of Silesia (SUM), Renal Research Institute [New York, NY, USA] (2RI), CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target): Giovambattista Capasso, Alexandre Andrade, Maie Bachmann, Inga Bumblyte, Adrian Constantin Covic, Pilar Delgado, Nicole Endlich, Andreas Engvig, Denis Fouque, Casper Franssen, Sebastian Frische, Liliana Garneata, Loreto Gesualdo, Konstantinos Giannakou, Dimitrios Goumenos, Ayşe Tuğba Kartal, Laila-Yasmin Mani, Hans-Peter Marti, Christopher Mayer, Rikke Nielsen, Vesna Pšić, Merita Rroji Molla, Giorgos Sakkas, Goce Spasovski, Kate I Stevens, Evgueniy Vazelov, Davide Viggiano, Lefteris Zacharia, Ana Carina Ferreira, Jolanta Malyszko, Ewout Hoorn, Andreja Figurek, Robert Unwin, Carsten A Wagner, Christoph Wanner, Annette Bruchfeld, Marion Pépin, Andrzej Wieçek, Dorothea Nitsch, Ivo Fridolin, Gaye Hafez, Maria José Soler, Michelangela Barbieri, Bojan Batinić, Laura Carrasco, Sol Carriazo, Ron Gansevoort, Gianvito Martino, Francesco Mattace Raso, Ionut Nistor, Alberto Ortiz, Giuseppe Paolisso, Daiva Rastenytė, Gabriel Stefan, Gioacchino Tedeschi, Ziad A Massy, Boris Bikbov, Karl Hans Endlich, Olivier Godefroy, Jean-Marc Chillon, Anastassia Kossioni, Justina Kurganaite, Norberto Perico, Giuseppe Remuzzi, Tomasz Grodzicki, Francesco Trepiccione, Carmine Zoccali, Mustafa Arici, Peter Blankestijn, Kai-Uwe Eckardt, Danilo Fliser, Eugenio Gutiérrez Jiménez, Maximilian König, Ivan Rychlik, Michela Deleidi, George Reusz, and Internal Medicine
- Subjects
ACIDOSIS ,[SDV]Life Sciences [q-bio] ,Review ,Disease ,electrolyte ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,0302 clinical medicine ,Child ,610 Medicine & health ,MUTATION ,0303 health sciences ,Kidney ,Proteinuria ,Reabsorption ,female genital diseases and pregnancy complications ,3. Good health ,[SDV] Life Sciences [q-bio] ,BARTTER-SYNDROME ,medicine.anatomical_structure ,Nephrology ,Child, Preschool ,GITELMANS-SYNDROME ,Kidney Diseases ,medicine.symptom ,Glomerular Filtration Rate ,medicine.medical_specialty ,brain ,chronic kidney disease ,cognitive function ,tubulointerstitial ,Urology ,Renal function ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,medicine ,Humans ,Renal Insufficiency, Chronic ,AcademicSubjects/MED00340 ,NEPHRITIS ,030304 developmental biology ,Rheumatology and Autoimmunity ,Transplantation ,Reumatologi och inflammation ,HYPONATREMIA ,business.industry ,urogenital system ,AQP2 ,medicine.disease ,Nephrogenic diabetes insipidus ,GENE ,KLOTHO ,MODEL ,Nephritis, Interstitial ,business ,Tubulointerstitial Disease ,Kidney disease - Abstract
Funding: This article is published as part of a supplement financially supported by the COST Action CA19127-Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT). Kidney function has two important elements: glomerular filtration and tubular function (secretion and reabsorption). A persistent decrease in glomerular filtration rate (GFR), with or without proteinuria, is diagnostic of chronic kidney disease (CKD). While glomerular injury or disease is a major cause of CKD and usually associated with proteinuria, predominant tubular injury, with or without tubulointerstitial disease, is typically non-proteinuric. CKD has been linked with cognitive impairment, but it is unclear how much this depends on a decreased GFR, altered tubular function or the presence of proteinuria. Since CKD is often accompanied by tubular and interstitial dysfunction, we explore here for the first time the potential role of the tubular and tubulointerstitial compartments in cognitive dysfunction. To help address this issue we selected a group of primary tubular diseases with preserved GFR in which to review the evidence for any association with brain dysfunction. Cognition, mood, neurosensory and motor disturbances are not well characterized in tubular diseases, possibly because they are subclinical and less prominent than other clinical manifestations. The available literature suggests that brain dysfunction in tubular and tubulointerstitial diseases is usually mild and is more often seen in disorders of water handling. Brain dysfunction may occur when severe electrolyte and water disorders in young children persist over a long period of time before the diagnosis is made. We have chosen Bartter and Gitelman syndromes and nephrogenic diabetes insipidus as examples to highlight this topic. We discuss current published findings, some unanswered questions and propose topics for future research. publishersversion published
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.